Valbiotis first — half 2026 net loss narrows to EUR 3.37 million; revenue more than doubles to EUR 765,000

Valbiotis posted H1 2026 net sales of EUR 765,000, up 130% year over year. Operating result narrowed to a loss of EUR 3.16 million, while net result improved to a loss of EUR 3.37 million. Operating expenses rose 8% to EUR 5.5 million, with sales and marketing costs up 16% to EUR 2.98 million. Cash and cash equivalents climbed to EUR 11.73 million at June 30, with a cash runway projected through end-2027. Valbiotis withdrew its 2026-2030 financial targets, citing below-expectation Q3 momentum and limited visibility beyond 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valbiotis SA published the original content used to generate this news brief via EQS News (Ref. ID: fr_reg_2414360_fr) on October 12, 2026, and is solely responsible for the information contained therein. (C)